CG Oncology reports data from Phase 3 bladder cancer study [Seeking Alpha]
CG Oncology, Inc. (CGON)
Company Research
Source: Seeking Alpha
The biotech company said the Phase 3 study showed 75.2% of patients , or 79 out of 105, achieved a complete response at any time, the primary endpoint of the study. The study is testing the drug in patients with high-risk non-muscle invasive bladder cancer that is unresponsive to Bacillus Calmette Geurin. The company presented the data at the annual meeting of the American Urological Association in San Antonio, Texas. Topline data from the study is expected by the end of the year. Last December, the FDA granted fast track and breakthrough therapy designations for cretostimogene. CG Oncology held its IPO in late January, raising $380M. Recommended For You More Trending News Recommended For You More Trending News About CGON Stock Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
CGON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CGON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CGON alerts
High impacting CG Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
CGON
News
- CG Oncology, Inc. (NASDAQ: CGON) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating. They now have a $50.00 price target on the stock.MarketBeat
- CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates [Yahoo! Finance]Yahoo! Finance
- CG Oncology Reports First Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewswire
- CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value [Seeking Alpha]Seeking Alpha
- CG Oncology, Inc. (NASDAQ: CGON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.MarketBeat
CGON
Sec Filings
- 5/16/24 - Form 4
- 5/16/24 - Form 3
- 5/9/24 - Form 8-K
- CGON's page on the SEC website